Clinical trials: Disseminated Fungal Infection
ICU, Invasive Pulmonary Aspergillosis
Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit in China
Invasive pulmonary aspergillosis (IPA) has traditionally been considered a disease of the severely immunocompromised host. However, emerging evidence over the past decade has identified severe influenza as a significant risk…
- Conditions
- ICU, Invasive Pulmonary Aspergillosis, Influenza A
- Trial name
- NCT07330986
- Testing
- IPA and non-IPA groups
- Where
- China
- Volunteers
- 542 people
- Sponsor
- Jianfeng Xie
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16…
- Trial name
- NCT00000907
- Where
- 24 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Candidiases
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.
Invasive fungal infection is detecting candida species in blood, cerebrospinal fluid, or urine. Clinical signs of invasive candidiasis may include lethargy, temperature instability, feeding intolerance, apnea, hypotension…
- Trial name
- NCT05848492
- Testing
- Fluconazole, Saline
- Where
- Pakistan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Candidemia
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in…
- Trial name
- NCT03604705
- Testing
- APX001
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Mycobacterium Avium-Intracellulare Infection, HIV Infections
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
To evaluate the efficacy and safety of two doses of azithromycin given chronically for the treatment of Mycobacterium avium bacteremia in AIDS patients.
- Trial name
- NCT00002090
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Pediatric, Cancer
Pharmacokinetics of Itraconazole in Pediatric Cancer Patients
This study investigated repeated-dose pharmacokinetics and safety of itraconazole and its active metabolite hydroxyitraconazole in pediatric cancer patients at risk for the development of invasive fungal disease.
- Trial name
- NCT01409018
- Testing
- Itraconazole
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Seoul National University Hospital
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
To compare the effectiveness and toxicity of two combination drug treatment programs for the treatment of disseminated Mycobacterium avium infection in HIV seropositive patients.
- Trial name
- NCT00000641
- Testing
- Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate
- Where
- 16 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.
- Conditions
- Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis
- Trial name
- NCT05897294
- Testing
- Voriconazole Inhalation Powder
- Sponsor
- TFF Pharmaceuticals, Inc.
Invasive Mycosis
Perception and Prevalence of Fungal Infections in Berlin - Brandenburg
This is a structured web-based survey in selected hospitals with intensive care units in Berlin- Brandenburg that will focus on the analysis of current knowledge in ICUs in the field of invasive mycoses.
- Trial name
- IFI_ICU (NCT01393002)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Charite University, Berlin, Germany
Invasive Candidiasis, Candidemia
Genetic Susceptibility Factors for Candidemia.
This is a prospective case-control physiopathological study, which main objective is to determine the genetic host factors predisposing to candidemia.
- Conditions
- Invasive Candidiasis, Candidemia, Genetic Predisposition to Disease
- Trial name
- NCT02841501
- Testing
- Analysis of genetic polymorphisms
- Where
- France
- Volunteers
- 453 people
- Sponsor
- University Hospital, Lille
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
This phase II trial studies how well isavuconazole works in preventing invasive fungal infections in adult patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome and neutropenia.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Neutropenia
- Trial name
- NCT03019939
- Testing
- Isavuconazole
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Mucormycosis
Mucorales PCR Screening in At-risk Hematology Patients
Patients with leukemia are treated with intensive chemotherapy and often have to undergo a stem cell transplantation which makes their immune system extremely vulnerable.
- Trial name
- MUCOPS (NCT05925660)
- Testing
- Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Invasive Fungal Disease
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days…
- Trial name
- NCT07135778
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cancer Survivor, Chronic Myeloproliferative Disorders
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT01077440
- Testing
- DNA analysis, polymerase chain reaction, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Invasive Fungal Infection
Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit
To investigate pharmacokinetics(PK) and pharmacodynamics(PD) of Caspofungin in ICU patients after received a loading dose of 70mg followed by 50mg (35mg if Child-Pugh score is 7-9), 40 patients will be recruited.
- Trial name
- NCT02510053
- Testing
- Caspofungin
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pulmonary Candidiasis, Invasive Candidiasis
Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?
In critically ill patients Candida spp. are frequently isolated from respiratory tract secretions such as endotracheal aspirates and bronchoalveolar lavages (BAL) and are most often considered as colonizers of the respiratory…
- Trial name
- NCT00786903
- Where
- Austria
- Volunteers
- 202 people
- Sponsor
- Robert Krause, MD
Graft vs Host Disease
Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients
Antifungal prophylaxis should be used in patients being treated with glucocorticoids for graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell transplantation (HSCT).
- Trial name
- ITRAG (NCT01282879)
- Testing
- Itraconazole
- Where
- 9 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Aspergillosis, Invasive Pulmonary
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
A standard treatment protocol for invasive aspergillosis (IA) will be implemented in several academic hematology centers in the Netherlands in which a diagnostic test demonstrating azole resistance by multiplex real-time…
- Trial name
- AzorMan (NCT03121235)
- Testing
- PCR based detection of azole resistance in A. fumigatus
- Where
- 8 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Erasmus Medical Center
Invasive Cryptococcosis
Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex
The purpose of this study is to determine if initial therapy with ABLC at 10/mg/kg/d for 7 days are at least effective as ABLC at 5.0 mg/kg/d X 14 days as induction treatment of patients with disseminated cryptococcosis and HIV.
- Trial name
- NCT01656382
- Testing
- ABLC
- Where
- United States
- Sponsor
- Medstar Health Research Institute